Downloads

31. Accelerating Cell Therapy Discovery With High-Throughput Electroporation 7/31/2026

    Discover how high-throughput electroporation-based screening can compress your CAR-T optimization timeline while delivering reproducible, scale-ready results across multiple donor samples.

32. Drug Discovery AI Has A Ground Truth Problem 7/27/2026

    If the goal is more healthy years of life, the bottlenecks are target identification, target validation, and clinical testing. Why is AI not transforming those steps? Because the data are not there.

33. Fragment-Based Drug Discovery 2.0, Part 2: Practical Workflow, Difficult Target Classes, And Emerging Capabilities 7/27/2026

    Part 2 focuses on the practical workflow, difficult target classes, emerging capabilities, and the criteria for translating these technologies into better discovery decisions.

34. Fragment-Based Drug Discovery 2.0, Part 1: Faster, Cleaner Weak-Binding Hit Discovery 7/24/2026

    This article examines the advances in ¹⁹F NMR, ultra-high-field instrumentation, and contrast-engineered screening.

35. PROTACs Offer Faster Proof Of Concept, But Glues May Broaden Patient Access 7/23/2026

    Maria Soloveychik says PROTACs are often easier to design rationally because they can be built from known ligands and optimized through linker chemistry, making them useful for early clinical proof of concept.

36. More Approvals, Broader Indications Could Make TPD A Mainstream Modality 7/23/2026

    Johannes Yeh says targeted protein degradation will feel mainstream when the field sees more FDA approvals, stronger clinical follow-up, and expansion beyond oncology into areas such as cardiovascular disease, Alzheimer’s, autoimmune disease, and diabetes.

37. Beyond Cereblon: Expanding The E3 Ligase Universe 7/23/2026

    Maria Soloveychik says her company was founded to tackle challenging targets using proximity-based modalities, beginning with PPI disruption before expanding into novel small-molecule molecular glue degraders.

38. 600 Ligases, Endless Possibilities 7/23/2026

    Maria Soloveychik says more than 600 E3 ligases offer a large opportunity for targeted protein degradation, with efforts underway to develop ligands against many of them.

39. Which Discovery Technologies Help Solve Degrader Assay Gaps 7/23/2026

    Johannes Yeh says degrader discovery requires robust screening systems to measure target engagement, ternary complex formation, stability, and degradation, supported by tools such as CRISPR, shRNA, and proteomics.

40. FDA Approval Proof Point Not Enough To Inform Other TPD Targets 7/23/2026

    Maria Soloveychik says the approval of a bivalent degrader is an important proof point for the field, showing that these compounds can work clinically much like molecular glues. However, she cautions that one approved molecule does not necessarily validate other targets, mechanisms, or compound pharmacologies.